376 related articles for article (PubMed ID: 17709797)
1. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
Zinzani PL; Musuraca G; Tani M; Stefoni V; Marchi E; Fina M; Pellegrini C; Alinari L; Derenzini E; de Vivo A; Sabattini E; Pileri S; Baccarani M
J Clin Oncol; 2007 Sep; 25(27):4293-7. PubMed ID: 17709797
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
O'Connor OA; Wright J; Moskowitz C; Muzzy J; MacGregor-Cortelli B; Stubblefield M; Straus D; Portlock C; Hamlin P; Choi E; Dumetrescu O; Esseltine D; Trehu E; Adams J; Schenkein D; Zelenetz AD
J Clin Oncol; 2005 Feb; 23(4):676-84. PubMed ID: 15613699
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
[TBL] [Abstract][Full Text] [Related]
7. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM
J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Hamilton AL; Eder JP; Pavlick AC; Clark JW; Liebes L; Garcia-Carbonero R; Chachoua A; Ryan DP; Soma V; Farrell K; Kinchla N; Boyden J; Yee H; Zeleniuch-Jacquotte A; Wright J; Elliott P; Adams J; Muggia FM
J Clin Oncol; 2005 Sep; 23(25):6107-16. PubMed ID: 16135477
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Shah MH; Young D; Kindler HL; Webb I; Kleiber B; Wright J; Grever M
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6111-8. PubMed ID: 15447997
[TBL] [Abstract][Full Text] [Related]
14. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
15. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
O'Connor OA; Moskowitz C; Portlock C; Hamlin P; Straus D; Dumitrescu O; Sarasohn D; Gonen M; Butos J; Neylon E; Hamelers R; Mac-Gregor Cortelli B; Blumel S; Zelenetz AD; Gordon L; Wright JJ; Vose J; Cooper B; Winter J
Br J Haematol; 2009 Apr; 145(1):34-9. PubMed ID: 19220284
[TBL] [Abstract][Full Text] [Related]
16. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
Reece DE; Rodriguez GP; Chen C; Trudel S; Kukreti V; Mikhael J; Pantoja M; Xu W; Stewart AK
J Clin Oncol; 2008 Oct; 26(29):4777-83. PubMed ID: 18645194
[TBL] [Abstract][Full Text] [Related]
18. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
O'Connor OA; Portlock C; Moskowitz C; Hamlin P; Straus D; Gerecitano J; Gonen M; Dumitrescu O; Sarasohn D; Butos J; Neylon E; Mac-Gregor Cortelli B; Blumel S; Evens AM; Zelenetz AD; Wright J; Cooper B; Winter J; Vose J
Clin Cancer Res; 2010 Jan; 16(2):719-26. PubMed ID: 20068103
[TBL] [Abstract][Full Text] [Related]
19. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
Blaney SM; Bernstein M; Neville K; Ginsberg J; Kitchen B; Horton T; Berg SL; Krailo M; Adamson PC
J Clin Oncol; 2004 Dec; 22(23):4804-9. PubMed ID: 15570082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
